Recent articles primelines

Interesting Articles From the Literature Highlighting Developments in Breast, Colorectal, and Pancreatic Cancer

  • Recommendations for Therapy Escalation in Early Breast Cancer. At the 15th St Gallen International Breast Cancer Conference 2017, an expert panel reviewed new data on treatment paradigms for early breast cancer and issued new recommendations based on their review. The panel recommendations cover locoregional and systemic therapy for early breast cancer, and include a focus on reducing surgical morbidity, use of adjuvant therapy in high-risk patients to include ovarian suppression (premenopause) or extend therapy (post-menopause), and strategies to prevent breast cancer recurrence.
    Ann Oncol. 2017 June 21. [Epub ahead of print].
  • Impact of Aspirin Use on Survival in Patients with Colorectal Cancer. This interesting article examines the relationship between the regular use of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) and survival in patients with colorectal cancer (CRC). After a median follow-up of 10.8 years, researchers found that the use of any NSAID after diagnosis was associated with improved survival among those patients with KRAS wild-type tumors, but not for those with KRAS-mutant disease.
    J Clin Oncol. 2017 June 15. [Epub ahead of print].
  • Biomarkers for Pancreatic Cancer. Current survival rates for patients with pancreatic cancer are poor, with few treatment options for patients who cannot be cured by surgical resection. This review provides an update on the current status of using biomarkers for the early detection of pancreatic adenocarcinoma, including the current use and limitations of CA 19-9, and what new biomarkers are on the horizon. Significant research is focused on identifying new biomarkers for early detection of pancreatic cancer as well as treatment-predictive and prognostic markers to help develop personalized treatment strategies.
    Tumor Biol. 2017;39(6):1-11.


Clinical Opinion Poll

When would you recommend dabrafenib + trametinib combo for a patient with advanced, symptomatic, PD-L1–low, lung adenocarcinoma and BRAF V600 mutation?